Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives

Abhijeet Singh, 1 Rajendra Prasad, 1, 2 Viswesvaran Balasubramanian, 1 Nikhil Gupta 3 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, Delhi 110007, India; 2Department of Pulmonary Medicine, King George Medical University, Lucknow, Uttar Pradesh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Singh A, Prasad R, Balasubramanian V, Gupta N
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
hiv
Acceso en línea:https://doaj.org/article/508928892d8c4092b241fec48e3debad
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:508928892d8c4092b241fec48e3debad
record_format dspace
spelling oai:doaj.org-article:508928892d8c4092b241fec48e3debad2021-12-02T09:50:59ZDrug-Resistant Tuberculosis and HIV Infection: Current Perspectives1179-1373https://doaj.org/article/508928892d8c4092b241fec48e3debad2020-01-01T00:00:00Zhttps://www.dovepress.com/drug-resistant-tuberculosis-and-hiv-infection-current-perspectives-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Abhijeet Singh, 1 Rajendra Prasad, 1, 2 Viswesvaran Balasubramanian, 1 Nikhil Gupta 3 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, Delhi 110007, India; 2Department of Pulmonary Medicine, King George Medical University, Lucknow, Uttar Pradesh 226003, India; 3Department of Internal Medicine, Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh 226010, IndiaCorrespondence: Rajendra PrasadDepartment of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, Delhi 110007, IndiaTel +91 9415 021 590Email rprasaddirvpci@gmail.comAbstract: Drug-resistant tuberculosis (DR-TB), including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is considered a potential obstacle for elimination of TB globally. HIV coinfection with M/XDR-TB further complicates the scenario, and is a potential threat with challenging management. Reports have shown poor outcomes and alarmingly high mortality rates among people living with HIV (PLHIV) coinfected with M/XDR-TB. This coinfection is also responsible for all forms of M/XDR-TB epidemics or outbreaks. Better outcomes with reductions in mortality have been reported with concomitant treatment containing antiretroviral drugs for the HIV component and antitubercular drugs for the DR-TB component. Early and rapid diagnosis with genotypic tests, prompt treatment with appropriate regimens based on drug-susceptibility testing, preference for shorter regimens fortified with newer drugs, a patient-centric approach, and strong infection-control measures are all essential components in the management of M/XDR-TB in people living with HIV.Keywords: drug-resistant, HIV, multidrug-resistant, extensively drug-resistant, tuberculosisSingh APrasad RBalasubramanian VGupta NDove Medical Pressarticledrug resistanthivmultidrug resistantextensively drug resistanttuberculosisImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 12, Pp 9-31 (2020)
institution DOAJ
collection DOAJ
language EN
topic drug resistant
hiv
multidrug resistant
extensively drug resistant
tuberculosis
Immunologic diseases. Allergy
RC581-607
spellingShingle drug resistant
hiv
multidrug resistant
extensively drug resistant
tuberculosis
Immunologic diseases. Allergy
RC581-607
Singh A
Prasad R
Balasubramanian V
Gupta N
Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
description Abhijeet Singh, 1 Rajendra Prasad, 1, 2 Viswesvaran Balasubramanian, 1 Nikhil Gupta 3 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, Delhi 110007, India; 2Department of Pulmonary Medicine, King George Medical University, Lucknow, Uttar Pradesh 226003, India; 3Department of Internal Medicine, Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh 226010, IndiaCorrespondence: Rajendra PrasadDepartment of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, Delhi 110007, IndiaTel +91 9415 021 590Email rprasaddirvpci@gmail.comAbstract: Drug-resistant tuberculosis (DR-TB), including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is considered a potential obstacle for elimination of TB globally. HIV coinfection with M/XDR-TB further complicates the scenario, and is a potential threat with challenging management. Reports have shown poor outcomes and alarmingly high mortality rates among people living with HIV (PLHIV) coinfected with M/XDR-TB. This coinfection is also responsible for all forms of M/XDR-TB epidemics or outbreaks. Better outcomes with reductions in mortality have been reported with concomitant treatment containing antiretroviral drugs for the HIV component and antitubercular drugs for the DR-TB component. Early and rapid diagnosis with genotypic tests, prompt treatment with appropriate regimens based on drug-susceptibility testing, preference for shorter regimens fortified with newer drugs, a patient-centric approach, and strong infection-control measures are all essential components in the management of M/XDR-TB in people living with HIV.Keywords: drug-resistant, HIV, multidrug-resistant, extensively drug-resistant, tuberculosis
format article
author Singh A
Prasad R
Balasubramanian V
Gupta N
author_facet Singh A
Prasad R
Balasubramanian V
Gupta N
author_sort Singh A
title Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
title_short Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
title_full Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
title_fullStr Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
title_full_unstemmed Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
title_sort drug-resistant tuberculosis and hiv infection: current perspectives
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/508928892d8c4092b241fec48e3debad
work_keys_str_mv AT singha drugresistanttuberculosisandhivinfectioncurrentperspectives
AT prasadr drugresistanttuberculosisandhivinfectioncurrentperspectives
AT balasubramanianv drugresistanttuberculosisandhivinfectioncurrentperspectives
AT guptan drugresistanttuberculosisandhivinfectioncurrentperspectives
_version_ 1718398002876383232